Three spin-off companies were created over the past years on the basis of previous research in the IRC.
ActoGeniX (created in 2006)
ActoGeniX exploits the proprietary TopAct™ platform for oral delivery of biopharmaceuticals. The company is developing a diverse portfolio of therapeutic products addressing major diseases with a high medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic disease. ActoGeniX’ initial focus is on gastrointestinal diseases and its lead product has already been successfully tested in a clinical trial with Crohn’s Disease patients.
Based on technology developed in the IRC for the use of Lactococcus lactis as a vehicle for therapeutical protein delivery in the gut.
- Publications from the former IRC unit of Applied Molecular Bacteriology, headed by Erik Remaut
- Key papers:
- Braat, H, Rottiers, P, Hommes, DW, Huyghebaert, N, Remaut, E, Remon, JP, van Deventer, SJ, Neirynck, S, Peppelenbosch, MP, Steidler, L.
A phase I trial with transgenic bacteria expressing Interleukin-10 in Crohn's disease
Clin Gastroenterol Hepatol 4, 754-759, 2006.
- Steidler, L, Neirynck, S, Huyghebaert, N, Snoeck, V, Vermeire, A, Goddeeris, B, Cox, E, Remon, JP, Remaut, E.
Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10
Nat Biotechnol 21, 785-789, 2003.
- Steidler, L, Hans, W, Schotte, L, Neirynck, S, Obermeier, F, Falk, W, Fiers, W, Remaut, E.
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
Science 289, 1352-1355, 2000.
Oxyrane Belgium (created in 2008)
Oxyrane Belgium ...(to be completed)
Q-Biologicals (created in 2011)
Q-Biologicals ...(to be completed)